An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder
A legfontosabb adatok
- Ki végzi
- Jonathan Santoro
- Hol
- Los Angeles (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 2. fázis
- Résztvevők
- 20 fő, tervezett
- Kezdés
- 2026. okt. 1.
- Várható befejezés
- 2030. dec. 1.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Ublituximab
- A regiszteradat frissítve
- 2026. szeptember 23.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with Down syndrome who have Down Syndrome Regression Disorder (DSRD). Their DSRD did not improve enough with first-line treatment.
- Életkor
- 18 to 40 years
- Nem
- All sexes
- A betegség stádiuma
- Possible or probable DSRD based on the 2022 International Consensus Criteria. Down syndrome must be trisomy 21 or translocation type.
- Korábbi kezelés
- First-line treatment (for example lorazepam, SSRIs, corticosteroids and/or IVIg) must have given partial response (10-50% improvement) or no response (<10% improvement) after 3 months. No IVIg within 8 weeks and no immunosuppressive drugs within 12 weeks before the start. No prior chemotherapy drugs such as methotrexate or cyclophosphamide.
A részvétel fő kizáró okai
- Mosaic Down syndrome, or weight < 40 kg (88 lb)
- Pregnancy or breastfeeding, or current or past tobacco smoking
- History of cancer, solid organ transplant, moyamoya syndrome or stroke
- Serious active or long-term infection, including HBV, HCV, TB or HIV
- Serious heart disease, clotting disorder or untreated thyroid disease
A regiszter feltételei, szó szerint
Mind a 34 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18 to 40 years, inclusive at time of consent
- Diagnosis of Down syndrome (trisomy 21 or translocation type)
- Diagnosis of possible or probable Down Syndrome Regression Disorder (DSRD) based on 2022 International Consensus Criteria
- History of partial response or non-response to first-line treatment (e.g., lorazepam, SSRIs, corticosteroids, and/or IVIg). Partial response = 10-50% improvement, Non-response = <10% improvement, Based on BFCRS or NPI-Q after 3 months of treatment
- Ability to attend all study visits with a study partner or legally authorized representative
- Study partner willing to comply with all study procedures
- Willingness to complete required washout periods for medications that may interfere with the study
- Highly effective contraception for reproductive participants and partners of childbearing potential
- Study partner/LAR sufficiently proficient in English to complete assessments
Ki nem vehet részt
- Use of IVIg within 8 weeks prior to baseline
- Use of immunosuppressive drugs within 12 weeks prior to baseline
- Prior treatment with anti-CD20 or B-cell therapies within required washout unless B-cell recovery criteria are met
- Any prior use of chemotherapeutic agents (e.g., methotrexate, cyclophosphamide)
- Receipt of live or live-attenuated vaccines within 4 weeks prior to treatment
- Prior neurosurgical intervention (exceptions for longstanding shunts)
- Current investigational therapy/prohibited medications
- Requirement for B-cell recovery >50 cells/μL after prior anti-CD20 therapy
- Mosaic Down syndrome
- History of solid organ transplant
- Clinically significant cardiac disease, clotting disorder, or other serious medical condition
- Active or chronic infection of clinical significance (including HBV, HCV, TB, HIV per protocol criteria)
- History of malignancy
- Untreated thyroid disease (hypo- or hyperthyroidism)
- History of moyamoya syndrome or stroke
- Detailed HBV, HCV, and TB criteria
- Weight < 40 kg at screening
- Pregnancy or breastfeeding
- Current or past tobacco smoking
- Poor venous access or inability to comply with IV procedures
- Other immunosuppressive biologics within 24 months
- Recent receipt of blood or plasma products (≤30 days)
- Abnormal screening labs indicating unacceptable risk
- Wards of the state
- Employees or students of Children's Hospital Los Angeles (CHLA)
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 40 év között vagy?
Helyszínek itt: Egyesült Államok
- Children's Hospital Los AngelesLos Angeles, Egyesült ÁllamokContact: Mariam YousufToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to evaluate whether the monoclonal antibody ublituximab can treat Down Syndrome Regression Disorder (DSRD) by assessing its safety, tolerability, and preliminary efficacy in affected individuals. This study is conducted in adults aged 18-40 years with Down syndrome who have DSRD and have had an inadequate or partial response to first-line therapies.
A teljes eredeti leírásKevesebb
The main questions it aims to answer are:
* Does ublituximab demonstrate acceptable safety and tolerability, as measured by treatment-emergent adverse events from baseline through Week 24? * Does ublituximab lead to improvement in cognitive, neuropsychiatric, motor, and functional outcomes from baseline to Weeks 12 and 24?
This is a single-arm study, so there is no comparison group.
Participants will:
* Receive two intravenous infusions of ublituximab (150 mg on Day 1 and 450 mg on Day 15) * Attend study visits at Screening, Baseline (Day 1) , Week 2 (Day 15), Week 3, Week 6, Week 12, and Week 24 * Undergo clinical assessments, including neurological and physical exams and safety monitoring labs throughout the study * Complete cognitive, behavioral, and functional evaluations at Baseline, Week 12, and Week 24 * Provide blood samples for safety monitoring and research biomarker analyses
A vizsgálat csoportja
- UblituximabA vizsgált kezelés
Participants assigned to the Ublituximab arm will receive a fixed two-dose intravenous regimen consisting of 150 mg on Day 1 and 450 mg on Day 15. All participants will be followed for 24 weeks with regular safety monitoring, clinical assessments, and evaluation of cognitive, neuropsychiatric, and functional outcomes.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07812181: ki vehet részt
- A regiszteradat frissítve
- 2026. szeptember 23.